A potential ICI activity in oncogene-addicted NSCLC was documented in the phase 3 IMpower150 study: the addition of Atezolizumab to Bevacizumab plus chemotherapy resulted in a survival improvement in NSCLC patients, including patients with EGFR mutations or ALK translocations [68]. Here, ALK is linked to non-small cell lung carcinoma.